SEC Form 4 · accession 0001104659-17-050277
Axsome Therapeutics, Inc. · AXSM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Golubieski
Officer — Chief Financial Officer
Period of report
Aug 4, 2017
Accepted (ET)
Aug 8, 2017 · 4:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001579428
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $5.90 | Aug 4, 2017 | A | 132,000 | A | — | Aug 4, 2027 | Common Stock | 132,000 | 132,000 | D |
Explanation of responses
- F1The option will vest in equal annual installments over four years such that the option will be fully vested on August 4, 2021.